MX421100B - Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso - Google Patents

Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso

Info

Publication number
MX421100B
MX421100B MX2018009524A MX2018009524A MX421100B MX 421100 B MX421100 B MX 421100B MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 421100 B MX421100 B MX 421100B
Authority
MX
Mexico
Prior art keywords
arginine
methods
free
tnfr
fusion polypeptide
Prior art date
Application number
MX2018009524A
Other languages
English (en)
Spanish (es)
Other versions
MX2018009524A (es
Inventor
Ke Gong
Kevin Maloney
Roy Alston
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2018009524A publication Critical patent/MX2018009524A/es
Publication of MX421100B publication Critical patent/MX421100B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2018009524A 2011-07-01 2012-06-29 Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso MX421100B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161504110P 2011-07-01 2011-07-01
PCT/US2012/044988 WO2013006454A1 (en) 2011-07-01 2012-06-29 Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use

Publications (2)

Publication Number Publication Date
MX2018009524A MX2018009524A (es) 2021-11-16
MX421100B true MX421100B (es) 2025-02-10

Family

ID=46579322

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009524A MX421100B (es) 2011-07-01 2012-06-29 Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
MX2014000093A MX358137B (es) 2011-07-01 2012-06-29 Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014000093A MX358137B (es) 2011-07-01 2012-06-29 Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.

Country Status (13)

Country Link
US (2) US10995130B2 (enExample)
EP (1) EP2726090B1 (enExample)
JP (2) JP6463968B2 (enExample)
KR (1) KR102061355B1 (enExample)
CN (2) CN103930124B (enExample)
AU (2) AU2012279205B2 (enExample)
BR (1) BR112013033671B1 (enExample)
CA (1) CA2840711C (enExample)
DK (1) DK2726090T3 (enExample)
EA (1) EA026226B1 (enExample)
MX (2) MX421100B (enExample)
WO (1) WO2013006454A1 (enExample)
ZA (1) ZA201400490B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
SG10201601621PA (en) 2011-06-28 2016-04-28 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
CA2840711C (en) 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
IN2014CN02527A (enExample) * 2011-10-18 2015-06-26 Coherus Biosciences Inc
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
LT2892550T (lt) 2012-09-07 2020-04-10 Coherus Biosciences, Inc. Stabilios adalimumabo vandeninės kompozicijos
CA2882551A1 (en) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
JP6026002B2 (ja) * 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とFcドメインを融合した融合タンパク質の安定化用組成物
MX2015015051A (es) * 2013-05-02 2016-06-10 Mabxience S A Formulaciones alternativas para polipeptidos de fusion tnfr:fc.
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Meiji Seikaファルマ株式会社 安定化されたポリペプチド水性製剤
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
LT2946765T (lt) 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
BR112017013269A2 (pt) 2014-12-22 2018-02-27 Ares Trading S.A. ?composição farmacêutica líquida?
KR20240132521A (ko) * 2015-03-13 2024-09-03 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN118510549A (zh) * 2021-09-22 2024-08-16 圣诺制药公司 具有减小的纳米颗粒尺寸和改善的多分散性指数的纳米颗粒药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
EP1946776B1 (en) * 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
KR100471843B1 (ko) 2002-06-11 2005-03-08 현대자동차주식회사 자동차의 아웃사이드 웨더스트립 장착구조
SI3417875T1 (sl) 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
EP1603596B1 (en) * 2003-02-28 2008-05-07 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding protein tbp-1
EP1654281A1 (en) * 2003-08-01 2006-05-10 Amgen, Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
EP3673919A1 (en) * 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
CA2840711C (en) 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use

Also Published As

Publication number Publication date
US10995130B2 (en) 2021-05-04
KR20140056218A (ko) 2014-05-09
CA2840711A1 (en) 2013-01-10
AU2017265026B2 (en) 2019-10-24
JP2014518276A (ja) 2014-07-28
CA2840711C (en) 2023-10-17
US11834491B2 (en) 2023-12-05
BR112013033671A2 (pt) 2017-01-24
CN103930124B (zh) 2021-05-11
MX2018009524A (es) 2021-11-16
EP2726090A1 (en) 2014-05-07
DK2726090T3 (da) 2020-01-20
JP6463968B2 (ja) 2019-02-06
US20210309719A1 (en) 2021-10-07
ZA201400490B (en) 2017-09-27
EP2726090B1 (en) 2020-01-01
EA201490195A1 (ru) 2014-04-30
WO2013006454A1 (en) 2013-01-10
NZ620160A (en) 2016-07-29
KR102061355B1 (ko) 2019-12-31
JP2017186349A (ja) 2017-10-12
AU2012279205A1 (en) 2014-02-06
CN103930124A (zh) 2014-07-16
EA026226B1 (ru) 2017-03-31
US20140255400A1 (en) 2014-09-11
BR112013033671B1 (pt) 2022-10-18
AU2012279205B2 (en) 2017-08-31
MX2014000093A (es) 2014-11-12
CN113244374A (zh) 2021-08-13
AU2017265026A1 (en) 2017-12-07
MX358137B (es) 2018-08-06

Similar Documents

Publication Publication Date Title
MX421100B (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
MX2023013729A (es) Receptores quimericos de flt3 y metodos de uso de los mismos.
PH12016502482A1 (en) Process for the purification of tnfr:fc fusion protein
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
MX2015012553A (es) Variantes de fc.
EA202091342A3 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
MX2016010953A (es) Proteinas de fc multimericas.
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
EA201690992A1 (ru) Антитела, специфичные к fcrn
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
WO2014184545A3 (en) Engineered fc variants
BR112015009462A2 (pt) composição farmacêutica estável do tnfr:fc proteína de fusão
MX2015016054A (es) Terapia de combinacion anti-quimiocina del ligando 2 del motif c-c y anti-lisil oxidasa-tipo 2 para el tratamiento de escleroderma.
WO2015164364A3 (en) Methods to manipulate alpha-fetoprotein (afp)
MX2014005651A (es) Composiciones de poliolefinas autoemulsionantes.
EA201491957A1 (ru) Антитела к ccl2 для лечения склеродермии
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии